CC Quote, Financials, Valuation and Earnings

Huntsman Corp. has a net margin of 4.01% compared to The Chemours Co.'s net margin of -0.69%. The Chemours Co.'s return on equity of -69.66% beat Huntsman Corp.'s return on equity of -8.07%.

The Chemours Co. has a consensus price target of $16.33, signalling upside risk potential of 8.96%. On the other hand Huntsman Corp. has an analysts' consensus of $10.81 which suggests that it could fall by -3.33%. Given that The Chemours Co. has higher upside potential than Huntsman Corp., analysts believe The Chemours Co. is more attractive than Huntsman Corp..

The Chemours Co. has a beta of 1.605, which suggesting that the stock is 60.526% more volatile than S&P 500. In comparison Huntsman Corp. has a beta of 0.683, suggesting its less volatile than the S&P 500 by 31.652%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.42%. Huntsman Corp. offers a yield of 7.49% to investors and pays a quarterly dividend of $0.09 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Huntsman Corp. pays out 174% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Chemours Co. quarterly revenues are $1.5B, which are larger than Huntsman Corp. quarterly revenues of $1.5B. The Chemours Co.'s net income of $60M is higher than Huntsman Corp.'s net income of -$10M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Huntsman Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.38x versus 0.33x for Huntsman Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Innospec, Inc. has a net margin of 4.01% compared to The Chemours Co.'s net margin of 2.92%. The Chemours Co.'s return on equity of -69.66% beat Innospec, Inc.'s return on equity of -0.1%.

The Chemours Co. has a consensus price target of $16.33, signalling upside risk potential of 8.96%. On the other hand Innospec, Inc. has an analysts' consensus of $99.33 which suggests that it could grow by 22.02%. Given that Innospec, Inc. has higher upside potential than The Chemours Co., analysts believe Innospec, Inc. is more attractive than The Chemours Co..

The Chemours Co. has a beta of 1.605, which suggesting that the stock is 60.526% more volatile than S&P 500. In comparison Innospec, Inc. has a beta of 0.910, suggesting its less volatile than the S&P 500 by 9.027%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.42%. Innospec, Inc. offers a yield of 2.1% to investors and pays a quarterly dividend of $0.87 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Innospec, Inc. pays out 109.37% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Chemours Co. quarterly revenues are $1.5B, which are larger than Innospec, Inc. quarterly revenues of $441.9M. The Chemours Co.'s net income of $60M is higher than Innospec, Inc.'s net income of $12.9M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Innospec, Inc.'s PE ratio is 98.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.38x versus 1.14x for Innospec, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Paramount Gold Nevada Corp. has a net margin of 4.01% compared to The Chemours Co.'s net margin of --. The Chemours Co.'s return on equity of -69.66% beat Paramount Gold Nevada Corp.'s return on equity of -34.36%.

The Chemours Co. has a consensus price target of $16.33, signalling upside risk potential of 8.96%. On the other hand Paramount Gold Nevada Corp. has an analysts' consensus of $1.70 which suggests that it could fall by -1.73%. Given that The Chemours Co. has higher upside potential than Paramount Gold Nevada Corp., analysts believe The Chemours Co. is more attractive than Paramount Gold Nevada Corp..

The Chemours Co. has a beta of 1.605, which suggesting that the stock is 60.526% more volatile than S&P 500. In comparison Paramount Gold Nevada Corp. has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.562%.

The Chemours Co. has a quarterly dividend of $0.09 per share corresponding to a yield of 3.42%. Paramount Gold Nevada Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Chemours Co. pays 174.61% of its earnings as a dividend. Paramount Gold Nevada Corp. pays out -- of its earnings as a dividend.

The Chemours Co. quarterly revenues are $1.5B, which are larger than Paramount Gold Nevada Corp. quarterly revenues of --. The Chemours Co.'s net income of $60M is higher than Paramount Gold Nevada Corp.'s net income of -$4.3M. Notably, The Chemours Co.'s price-to-earnings ratio is 66.47x while Paramount Gold Nevada Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Chemours Co. is 0.38x versus -- for Paramount Gold Nevada Corp.. Usually stocks with elevated PS ratios are considered overvalued.